This is a review on particle therapy for GI cancers including esophageal, pancreatic, liver and anorectal cancers. Key dosimetric and clinical data of proton and carbon ion therapy for these GI cancers are discussed. The author concluded that the use of particle therapy in GI cancer seems safe and effective, however clinical data are scarce, with solid clinical data is only available for hepatocellular carcinoma (HCC). The higher costs of particle therapy can only be justified, if the dosimetric advantages translate into meaningful clinical advantages—either improved tumor control or reduced toxicity.